27th March, 2025
Next-Gen Continuous Glucose Monitoring Technology Sets New Industry Standard
The 2025 Advanced Technologies & Treatments for Diabetes (ATTD) conference took place in Amsterdam, Netherlands, bringing together top experts and the latest innovations in diabetes care. SIBIONICS participated in this prestigious event, unveiling the world's thinnest CGM device—GS3, showcasing its latest breakthrough in glucose monitoring technology.
SIBIONICS GS3 Achieves CE Certification
With its ultra-compact design and 3-second activation, GS3 quickly became a highlight at ATTD 2025 with its revolutionary thinness of just 2.9mm, comparable to a small coin. It offers:
In-Depth Exploration of CGM & CKM in Clinical Applications
At ATTD 2025, SIBIONICS hosted the SIBIONICS Symposium, where experts shared research findings on the clinical applications of CGM and the differentiation of AGP (Ambulatory Glucose Profile) patterns among various patient groups. These insights contribute to the advancement of precision diabetes treatment and offer stronger scientific and clinical support.
CKM made its debut at the symposium, where clinical experts conducted an in-depth study on its potential for Type 1 diabetes management and, for the first time, shared preliminary findings at the conference.
With the launch of GS3, SIBIONICS continues to lead CGM innovation, aiming to provide a lighter, more precise, and smarter glucose monitoring experience for people with diabetes worldwide.
Medtech Special
Artificial Intelligence Breakthroughs
Robots In Medtech
Asia Pacific
Global / International
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer